Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.
Davies
Christina
C
Clinical Trial Service and Epidemiological Studies Unit, Radcliffe Infirmary, University of Oxford, Oxford OX2 6HE, UK. christina.davies@ctsu.ox.ac.uk